We've documented the recent delay in Cronos' financials, and Medipharm's potential links to bulk sales and purchases of biomass. Our last structure on Medipharm Labs highlighted some margin slippa read more
We've documented the recent delay in Cronos' financials, and Medipharm's potential links to bulk sales and pu read more
Well, another day, another lawsuit. This time it's around a purchaser flaking on some $9MM+ of payables owing to Medipharm Labs over a white-label agreement gone bad. I'm a naturally curious guy, read more
Well, another day, another lawsuit. This time it's around a purchaser flaking on some $9MM+ of payables owing read more
In looking at $LABS’ last two sets of financials, we’ve noted their optionality and compensation levels. For the most part, how much the *suits* are getting paid is a relatively subjective exerci read more
In looking at $LABS’ last two sets of financials, we’ve noted their optionality and compensation levels. read more
We love nautical references here at TheCannalysts. Yet while we are analysts, we also hold some positions in legal cannabis companies as well. We'll always disclose, especially around anything we run read more
We love nautical references here at TheCannalysts. Yet while we are analysts, we also hold some positions in read more
The financials for mid-stream companies are welcome to me, because unlike producing, there is far less margin for error in processing - and cockups are far easier to spot early on. I haven’t loo read more
The financials for mid-stream companies are welcome to me, because unlike producing, there is far less margin read more
As we finally start getting "clean" (eg. with no need to back-out 9 month YTD from Annual Reports) Quarterly earnings reports from recently public US MSOs, we can start doing Peer Comparisons and Tr read more
As we finally start getting "clean" (eg. with no need to back-out 9 month YTD from Annual Reports) Quarterly read more